Navigation Links
Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program
Date:7/9/2008

ed for the treatment of a serious or life-threatening condition and that it has the potential to address unmet medical needs for the condition. Virulizin(R) is a registered trademark owned by Lorus Therapeutics Inc.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of novel therapeutics in cancer. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination with other drugs, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of Canadian and U.S. securities laws. Such statements include, but are not limited to, statements relating to: our research program plans, our plans to conduct clinical trials, the successful and timely completion of clinical studies and the regulatory approval process, our ability to fund future research, our plans to obtain partners to assist in the further development of our product candidates, the establishment of corporate alliances, the Company's plans, objectives, expectations and intentions and other statements including words such as "continue", "believe", "plan", "expect", "intend", "will", "should", "may", and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors cou
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
3. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
4. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
5. Lorus initiates development program exploring novel route of administration for LOR-2040
6. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
7. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... ... June 30, 2015 , ... This cutting edge standard making ... Featuring 12 distinct peaks, the WAV-8 is the world’s first cuvette-shaped, solid-state filter ... deep into the NIR range. Previous spectrophotometer calibration standards, such as those made from ...
(Date:6/29/2015)... 29, 2015 BioNano Genomics, Inc., the leader ... institutes, announced today that a collaboration led by the ... the creation of the first comprehensive analysis of a ... methods for sequencing and genome mapping. This study, published ... analysis of the contiguous diploid human genome assembly obtained ...
(Date:6/29/2015)... -- According to a new market research report ... Therapeutics, R&D), by Technology (SELEX, Other Technologies), by End Users ... Forecast to 2020", published by MarketsandMarkets, the global Aptamers Market ... Million in 2015, at a CAGR of 17.89%. ... F igures spread through 125 P ...
(Date:6/29/2015)... 29, 2015 Elsevier , ... products and services, today announced the highlights of its ... 2014 Journal Citation Reports® (JCR) published by Thomson Reuters, ... from 2013 to 2014, ahead of the aggregate across ... rank in 62 subject categories, up from 61 in ...
Breaking Biology Technology:FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 2FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 3BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 2BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 3Aptamers Market Worth $244.93 Million by 2020 2Aptamers Market Worth $244.93 Million by 2020 3Aptamers Market Worth $244.93 Million by 2020 4Elsevier Announces 2014 Citation Impact Highlights 2Elsevier Announces 2014 Citation Impact Highlights 3
... FOLD ) today announced that John Crowley, President and ... Merrill Lynch,Global Pharmaceutical, Biotech & Medtech 2007 Conference in ... BDT (11:00 am EDT) at the,Merrill Lynch Financial Centre. ... will be available to all,interested parties through the Investors ...
... a,biotechnology company translating the complexity of human biology ... president and,CEO, Dr. Keith O. Elliston, has been ... in Arlington, Va., September 17-18. Dr. Elliston ... Development and Commercial Value Added in Care Delivery ...
... ... and Reusable Bottles, MONROVIA, Calif., Sept. 12 Bottled or ... of consumers who fear the impact of,bottled water on the environment, ... assembled a family of products on its website, http://www.discovertesting.com, in ...
Cached Biology Technology:Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference 2Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference 3Genstruct CEO, Dr. Keith Elliston, Invited to Speak at Oncology Clinical Trial Summit 2Discover Testing Settles the Drinking Water Debate: Tap vs. Bottled 2
(Date:6/23/2015)... June 22, 2015 ... addition of the "Body-Worn Temperature Sensors Market ... and Forecast 2014 - 2020" report to ... analysis of the global body-worn temperature sensors market. ... segmented on the basis of types, care setting, ...
(Date:6/18/2015)... Conn. , June 18, 2015 NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market announces ... a featured segment on "Money on the Mark", scheduled to ... City June 20 th . ... will be from 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO ...
(Date:6/17/2015)... , June 17, 2015  Crossmatch™, a leading ... that its U.are.U ® 4500 fingerprint readers ... Eateries, Inc., a San Jose, ... to increase security, improve accountability and reduce fraud ... instant, non-repudiable identity confirmation for employee sign in ...
Breaking Biology News(10 mins):Body-Worn Temperature Sensors Market - Global Industry Analysis 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3
... today announced that it will launch EMBO Press on ... for The EMBO Journal , EMBO reports , ... provides opportunities for the future development of the journals. ... to encourage transparency in the publication process and help researchers make ...
... is derived from brain tumor stem cells, the source ... unclear. The potential of neural stem cells to transform ... but has not been confirmed. A team led by ... Nanjing Medical University, China found that doxycycline-induced neural stem ...
... Queen,s University Belfast is a lead partner in a ... new ways to treat Cystic Fibrosis. Affecting more ... is one of the most common life-threatening inherited diseases. ... death for patients., The new global programme, known as ...
Cached Biology News:EMBO announces the launch of EMBO Press 2Queen's University in €6m bid to find new Cystic Fibrosis treatments 2Queen's University in €6m bid to find new Cystic Fibrosis treatments 3
Attachments: Clip bar for tubes 10 to 19 mm in diameter Overall Dimension Height IC: 6 (15.2) Overall Dimension Length IC: 18.5 (46.9) Overall Dimension Width IC: 4 (10.2)...
For quantitative determination of Aldolase in Serum (an indicator of muscle damage). Ready-to-use liquid stable reagent. Formulated to eliminate interference from pyruvates. Application sheets are ...
BD FastImmune EDTA Solution. Applications: Flow Cytometry Storage Temperature: Refrigerate(2 to 8C)...
This Universal 24" X 18" (61 X 45.7cm.) shaker platforms will accept any Thermo Forma shaker flask clip....
Biology Products: